- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Large Cap High Growth Potential
U.S. Pharmaceuticals & Biotech Large Cap High Growth Potential
UPDATED Sep 22, 2022
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
15 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RPRXRoyalty Pharma | US$41.06 | -2.6% | 10.6% | US$24.9b | US$53.95 | PE38.5x | E54.5% | 1.9% | ||
| ALNYAlnylam Pharmaceuticals | US$202.71 | -2.8% | 8.4% | US$24.3b | US$237.77 | PS27.5x | E70.0% | n/a | ||
| INCYIncyte | US$67.41 | -2.3% | -3.4% | US$15.0b | US$88.47 | PE15.9x | E30.0% | n/a | ||
| SGENSeagen | US$140.55 | -0.5% | -15.4% | US$25.9b | US$183.43 | PS14.6x | E74.9% | n/a | ||
| LLYEli Lilly | US$310.87 | 0.5% | 33.9% | US$295.4b | US$335.71 | PE51.9x | E21.9% | 1.3% | ||
| ILMNIllumina | US$193.49 | -4.2% | -55.3% | US$30.4b | US$251.56 | PS6.5x | E69.1% | n/a | ||
| HZNPHorizon Therapeutics | US$62.63 | -1.4% | -42.8% | US$14.4b | US$105.64 | PE18.9x | E25.6% | n/a | ||
| BMYBristol-Myers Squibb | US$71.29 | -0.7% | 17.6% | US$152.2b | US$80.32 | PE23x | E22.1% | 3.0% | ||
| IQVIQVIA Holdings | US$190.62 | -8.1% | -27.3% | US$35.6b | US$269.11 | PE30.6x | E18.4% | 0% | ||
| BMRNBioMarin Pharmaceutical | US$84.92 | -3.6% | 7.1% | US$15.8b | US$114.14 | PE291.3x | E47.9% | n/a | ||
| TECHBio-Techne | US$290.22 | -8.3% | -45.9% | US$11.4b | US$473.45 | PE41.8x | E10.8% | 0.4% | ||
| RGENRepligen | US$189.94 | -18.2% | -41.4% | US$10.5b | US$266.56 | PE66.1x | E18.4% | n/a | ||
| BIOBio-Rad Laboratories | US$418.55 | -11.5% | -47.5% | US$12.4b | US$705.00 | PS4.3x | E81.1% | n/a | ||
| ZTSZoetis | US$149.46 | -6.1% | -27.0% | US$70.0b | US$225.64 | PE33.5x | E10.5% | 0.9% | ||
| ICLRICON | US$191.02 | -8.5% | -32.1% | US$15.6b | US$267.57 | PE74.2x | E29.4% | n/a |
Page 1 of 1